A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study

Trial Profile

A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2017

At a glance

  • Drugs RA 101495 (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Sponsors Ra Pharmaceuticals
  • Most Recent Events

    • 09 Aug 2017 According to a Ra Pharmaceuticals media release, the first two patients from the parent study (NCT03078582) successfully completed the Phase 2 study and have elected to continue treatment with RA101495 in a long-term extension study.
    • 22 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top